James T. Kurnick, M.D. is a physician-scientist based at the Massachusetts General Hospital where his research in cellular immunology has led to a successful therapy for Inflammatory Bowel Disease, (Entyvio) and a spin-off Biotechnology company, TriBiotica LLC, that is developing a new approach to treating cancer and other diseases where we can target the disease-causing cell (cancer, infection, autoimmunity, allergy). Jim has a longtime affiliation with Dunster House, including his undergraduate thesis in Biology with A. M. Pappenheimer, the Dunster House Master. In addition to his medical interests, Jim also completed a Master’s in Education at HUGSE to complement his activities as the Director of a course at the Harvard Medical School to introduce the subjects of Pathology, Immunology and Microbiology. Jim’s Research focuses on providing new targets for immune destruction of disease-causing cells, by assembling novel target molecules that make them stand out for destruction by the immune system.